Раннее применение МРТ-управляемой фокусировки ультразвука признано наиболее экономически эффективным методом лечения боли в Нидерландах

Моделирование показало, что раннее использование магнитно-резонансной фокусировки ультразвука (MR-HIFU) обеспечивает лучшее соотношение затрат и эффективности по сравнению с лучевой терапией. Исследование подтвердило, что этот метод с вероятностью 77% является оптимальным выбором при пороге готовности платить 80 000 евро за год качественной жизни.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Research Alert Authors: Julia Simões Corrêa Galendi, Ingrid Nijholt, Renée Hovenier, Jorik Slotman, Erik Phernambucq, Stephanie Stock, Clemens Bos, Manon Braat, Helena Verkooijen, Martijn Boomsma & Dirk Müller Abstract Introduction Non-randomized clinical trial has shown that Magnetic Resonance guided High-intensity focused ultrasound (MR-HIFU) leads to faster pain relief compared to the current standard of care External Beam Radiotherapy (EBRT). Objective To evaluate the cost-utility of ’early MR-HIFU’ (with optional EBRT afterwards) or ‘delayed MR-HIFU’ (i.e., MR-HIFU after failed EBRT) versus EBRT (with optional re-irradiation with EBRT) from the societal perspective in the Netherlands Methods A lifelong patient-level simulation model was developed. After a treatment with either MR-HIFU or EBRT, a patient could have: (i) complete pain relief, (ii) partial pain relief, (iii) persistent pain and (iv) death. We also accounted for the event of a pathological fracture. Model outputs were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). The net monetary benefit was calculated considering the willingness-to-pay threshold of €80,000 per QALY gained, adjusted by the Dutch disease severity index. Deterministic and probabilistic sensitivity analyses were conducted. Results The strategy ‘delayed MR-HIFU’ costs €706 more than EBRT, whilst ‘early MR-HIFU’ costs €1,875 more than EBRT.‘Early MR-HIFU’ adds 0,15 more QALYs than EBRT, resulting in an ICER of €12.755 per QALY and an incremental net monetary benefit of €8,631. At a threshold of 80,000€ per QALY there is a 77% probability that ‘early MR-HIFU’ is the most cost-effective option. Conclusion Although there are still uncertainties relating to implementation of MR-HIFU in patient care, our modelling study shows that offering MR-HIFU as an early treatment would be the most cost-effective option in the Netherlands.